
Vicks is owned by Procter & Gamble (P&G), a publicly traded American multinational consumer goods corporation. P&G acquired Vicks in 1985 through its purchase of Richardson-Vicks. The company is headquartered in Cincinnati, Ohio, USA.
Parent Company
Acquired
1985
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Vicks | Procter & Gamble Company | Wholly owned |
Vicks was founded in 1890 by Lunsford Richardson, a pharmacist from Selma, North Carolina. Richardson had been experimenting with menthol, a relatively new ingredient at the time, and developed a salve that combined menthol with camphor, eucalyptus oil, and other ingredients in a petroleum jelly base. He initially called the product Vicks Magic Croup Salve, naming it after his brother-in-law Joshua Vick, a successful pharmacist whose name Richardson believed would lend credibility to the product.
Richardson began selling his salve locally and through mail order, and the product gained a following for its effectiveness in relieving cold and croup symptoms. In 1905, he renamed the product Vicks VapoRub and moved his business to Greensboro, North Carolina, where he could better manage production and distribution.
The 1918 influenza pandemic was a pivotal moment for Vicks VapoRub. As the Spanish flu swept across the United States and the world, killing millions of people, Vicks VapoRub was widely used to relieve symptoms. The pandemic created enormous demand for the product, and Vicks became a household name across America. Sales reportedly increased from $900,000 in 1917 to $2.9 million in 1918.
Following the pandemic, Vicks continued to grow through aggressive marketing and product innovation. The company was one of the early adopters of radio advertising, using the new medium to reach consumers across the country. Vicks also pioneered direct mail marketing, sending samples to millions of American households.
The Richardson family sold Vicks Chemical Company to Procter & Gamble in 1985 as part of P&G's acquisition of Richardson-Vicks Inc. (which had been formed through various mergers). The acquisition price was approximately $1.24 billion, one of the largest consumer goods acquisitions of its time. The deal gave P&G the Vicks brand along with other Richardson-Vicks products including Oil of Olay (now Olay) and Pantene.
Under P&G's ownership, Vicks has continued to innovate and expand. The brand introduced Vicks VapoInhaler (a portable nasal inhaler), Vicks VapoCOOL (medicated drops), and various reformulations of its core products. P&G has also expanded Vicks internationally, making it one of the world's most recognized cold and flu remedy brands.
Vicks NyQuil and DayQuil have become among the best-selling over-the-counter cold and flu medications in the United States, with NyQuil in particular becoming culturally synonymous with nighttime cold relief.
Procter & Gamble delivered mixed financial results in fiscal 2026, reflecting both the strength of its business model and challenges in the current consumer environment. In Q2 2026, P&G reported adjusted earnings per share of $1.88, exceeding Wall Street expectations of $1.86, while revenue of $22.21 billion fell slightly short of analyst expectations of $22.28 billion. The company's ability to beat earnings estimates despite revenue challenges demonstrates the effectiveness of its productivity initiatives and cost management strategies.
Financial Performance Overview shows P&G's resilience in a challenging market. The company revised its fiscal 2026 earnings outlook to 1% to 6% net earnings per share growth, down from the previous forecast of 3% to 9%, citing higher restructuring charges. Despite this adjustment, P&G maintained its sales growth guidance, reflecting confidence in its business fundamentals and strategic positioning. CFO Andre Schulten noted that "We've now completed what we fully expect will be the softest quarter of the fiscal year," indicating anticipation of improved performance in the second half.
Volume Performance revealed significant challenges across key categories, with overall volume falling 1% as three out of five product categories reported shrinking volume. This decline reflects broader consumer behavior patterns as inflation-weary consumers hunt for deals and reduce discretionary spending, particularly in P&G's largest market, the United States. Despite these challenges, Schulten emphasized that "People have not stopped washing their hair, they still buy diapers, they do their laundry — albeit at a little bit slower pace, so the market growth has certainly slowed over the last 18 to 24 months."
Segment Performance showed divergent trends across P&G's business portfolio. The baby, feminine and family care segment experienced the steepest decline with volume falling 5% in Q2 2026, facing tough comparisons with the year-ago period when retailers and consumers stocked up ahead of expected port strikes. The grooming business, which includes Gillette and Venus razors, reported a 2% volume drop, reflecting ongoing competitive pressures in the men's grooming market. The health-care segment saw volume fall 1%, including brands like Oral-B, Vicks, and Pepto-Bismol.
Bright Spots in Performance were primarily in the beauty segment, which was the only division to report volume growth, rising 3% fueled by stronger demand for hair-care products. The fabric and home-care business, which includes brands like Febreze and Tide, reported unchanged volume, demonstrating stability in P&G's largest business segment by revenue. These performance variations highlight the importance of P&G's diversified portfolio strategy in navigating market challenges.
Q1 2026 Results demonstrated stronger performance compared to Q2, with net sales of $22.4 billion, up 3% versus the prior year, and organic sales increasing 2%. The company achieved diluted EPS of $1.95 (up 21% YoY) and core EPS of $1.99 (up 3% YoY), reflecting strong operational execution. Operating cash flow was $5.4 billion, and the company returned $3.8 billion to shareholders through dividend payments and share repurchases, demonstrating P&G's commitment to shareholder returns.
Consumer Market Dynamics continue to shape P&G's performance, with the company facing "softer consumer markets, aggressive competition, and a dynamic geopolitical landscape" according to CFO Schulten. These challenges reflect broader economic pressures affecting consumer spending patterns and competitive intensity in key categories. However, P&G expects stronger results in the second half of the fiscal year, fueled by upcoming innovation and improved market conditions.
Innovation and Demand Creation remain central to P&G's strategy for driving growth. The company is increasing investment in innovation and demand creation to improve value for consumers and drive category growth. This focus on innovation is particularly important in the beauty segment, where new product development and marketing initiatives have helped drive volume growth despite overall market challenges.
Q3 2026 Results showed a significant acceleration in performance. P&G reported net sales of $21.24 billion, up 7% versus the prior year, beating Wall Street expectations of $20.5 billion. Organic sales increased 3%, driven by a 2% increase in volume — the first time in a year that P&G reported growing volume across the company. Core EPS of $1.59 beat estimates of $1.56, up 3% YoY. Diluted EPS was $1.63, up 6%, boosted by a gain from the dissolution of the Glad joint venture business. CEO Shailesh Jejurikar stated: "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions." All five segments posted net sales growth: Beauty +11% ($3.87B), Fabric & Home Care +7% ($7.4B), Baby/Feminine/Family Care +6% ($5.06B), Health Care +7% ($3.07B), and Grooming +7% ($1.61B). The company returned $3.2 billion to shareholders via $2.5 billion in dividends and over $600 million in share repurchases. However, P&G warned about uncertainty from the Iran war's effects on input costs and consumer spending, projecting approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. If Brent crude stays around $100/barrel, P&G projects an annual after-tax headwind of $1 billion. The company will not provide a fiscal 2027 forecast until its July earnings report.
Leadership Transition Impact represents a significant element of P&G's current strategy. Shailesh Jejurikar's appointment as CEO effective January 1, 2026, brings fresh perspectives while maintaining continuity through Jon Moeller's transition to Executive Chairman. Jejurikar described his vision at the CAGNY Conference: leveraging P&G's strengths to "create the CPG company of the future."
Geographic Performance varied across P&G's global markets, with the United States facing particular challenges due to consumer behavior changes and competitive pressures. However, the company's global diversification provides stability, with different regions experiencing varying levels of economic pressure and consumer demand patterns.
Supply Chain and Operations have been optimized to support P&G's productivity initiatives and cost management strategies. The company's integrated supply chain encompasses suppliers, manufacturing partners, and retailers in complex networks ensuring product availability worldwide while maintaining operational efficiency.
Future Outlook remains cautiously optimistic, with P&G maintaining its fiscal year 2026 guidance for all-in sales growth of 1% to 5% and net EPS growth of 1% to 6% versus FY2025 diluted EPS of $6.51. Core EPS growth guidance is in-line to up 4% versus FY2025 core EPS of $6.83, equating to $6.83 to $7.09 per share. However, earnings are expected to trend toward the lower end of the range as cost headwinds persist and investments step up. The company faces approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. P&G will not provide a fiscal 2027 forecast until its July 2026 earnings report, citing uncertainty from the Iran war's impact on input costs and consumer spending.
Investor Confidence remained strong despite mixed results, with P&G shares rising more than 2% in morning trading following the Q2 earnings announcement. This positive market response reflects investor confidence in P&G's ability to navigate current challenges while positioning for future growth through strategic initiatives and operational excellence.
P&G's recent performance demonstrates the company's ability to maintain profitability and shareholder returns while navigating challenging market conditions. The combination of operational efficiency, brand strength, and strategic focus on innovation provides a solid foundation for continued success in the competitive consumer goods industry.
Vicks operates under Procter & Gamble's sustainability framework, which focuses on climate action, waste reduction, water stewardship, and nature preservation. P&G's ambition is to reach net zero greenhouse gas emissions across its supply chain and operations from raw material to retailer by 2040.
Climate Targets: P&G has set near-term science-based targets for 2030, including a 65% reduction in Scope 1 and 2 emissions from a 2010 baseline. As of fiscal year 2025, P&G has achieved a 61% reduction in Scope 1 and 2 emissions. The company aims to purchase 100% renewable electricity globally by 2030, with more than 99% already sourced from renewable sources as of 2025. P&G's total carbon footprint was approximately 2.16 million tCO2e in 2024, with Scope 1 and 2 emissions representing approximately 2% of the total footprint.
Sustainable Packaging: P&G aims to design all consumer packaging to be recyclable or reusable by 2030. As of 2025, 80% of consumer packaging is designed to be recyclable or reusable, up from 55% in 2020. The company has achieved a 21% reduction in virgin petroleum plastic per unit of production for consumer packaging since a 2017 baseline, working toward a 50% reduction goal. Vicks contributes to these packaging goals through initiatives for VapoRub containers, liquid medication bottles, and other product packaging.
Supply Chain Engagement: P&G's Climate Unlock Program, launched in 2023, helps suppliers progress toward net zero through education, resources, and training. The program includes Schneider Electric's Accelerate Renewable Electricity program and GHG reduction planning support. P&G has achieved an 11% reduction in supply chain emissions per unit versus a 2020 baseline, working toward a 40% reduction goal by 2030.
Responsible Sourcing: P&G sources 100% third-party certified responsibly sourced palm oil and wood pulp for its brands. The company partners with organizations like Circulate Capital and the Alliance to End Plastic Waste to drive greater circularity in packaging and reduce plastic leakage into the environment.
Community Impact: Vicks contributes to community health through educational programs about cold and flu prevention, supporting healthcare access in underserved communities, and promoting public health awareness. P&G's broader social impact programs focus on maternal and child health, education, and community development in regions where the brand operates.
Vicks has received recognition for product innovation, consumer trust, and brand longevity throughout its 135-year history.
Vicks has maintained a strong safety record throughout its 135-year history. The brand has faced typical pharmaceutical industry challenges and occasional regulatory scrutiny.
Vicks Sinus Steam Inhaler Recall (February 2026): Health Canada issued a recall for the Vicks Sinus Steam Inhaler (model VIH200CV1, lot 17824) in February 2026. The device, manufactured by Kaz USA Inc. (a Helen of Troy company, not P&G), was distributed in Canada without the required Medical Device License under Health Canada regulations. Consumers were advised to contact the manufacturer for questions. This recall involved a licensed Vicks-branded device manufactured by a third party, not a P&G-manufactured Vicks medication.
Regulatory Compliance: Vicks operates under strict regulatory oversight from the FDA and other health authorities for over-the-counter medications. The brand has maintained compliance with evolving regulatory requirements for OTC drug labeling, safety testing, and health claims across all markets. Vicks has adapted to changing requirements regarding ingredient disclosure, product claims, and safety standards.
Product Formulation Questions: Vicks has faced occasional questions about product formulations, particularly regarding menthol content in VapoRub and potential allergic reactions in sensitive individuals. The brand has responded through enhanced ingredient transparency, clearer usage instructions, and product lines for consumers with sensitive skin or respiratory conditions.
Market Pressures: Vicks faces intense competition from Robitussin (Haleon), Mucinex (Reckitt), Theraflu (Haleon), and store-brand cold remedies. The brand has navigated pricing pressure from generic alternatives and changing consumer preferences for natural remedies through product innovation and maintaining its positioning as a trusted cold and flu solution.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Procter Gamble | USA | 1901 | Mass market | Global | Unisex |
Market Positioning: Vicks competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Procter & Gamble Company, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Vicks which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Vicks which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
Bausch + Lomb operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Vicks which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.